title: Single arc volumetric modulated arc therapy for complex brain gliomas: is there an advantage as compared to intensity modulated radiotherapy or by adding a partial arc?
abstract: The objective of this study was to determine if volumetric modulated arc therapy (VMAT) offers advantages over intensity modulated radiotherapy (IMRT) for complex brain gliomas and evaluate the role of an additional partial arc. Twelve patients with glioma involving critical organs at risk (OAR) were selected [six low grade brainstem glioma (BG) and six glioblastoma (GB) cases]. BGs were prescribed 54 Gy/30 fractions (frx), and GB treated to 50 Gy/30 frx to a lower dose PTV (PTV50) with a simultaneous integrated boost delivering a total dose of 60 Gy/30 frx to a higher dose PTV (PTV60). VMAT was planned with a single arc (VMAT1) and with an additional coplanar partial arc spanning 90° (VMAT2). We observed VMATI improving the PTV equivalent uniform dose (EUD) for BG cases (p=0.027), improving the V95 for the PTV50 in GB cases (p=0.026) and resulting in more conformal GB plans (p=0.008) as compare to IMRT. However, for the GB PTV60, IMRT achieved favorable V95 over VMAT1 and VMAT2 (0.0046 and 0.008, respectively). The GB total integral dose (ID) was significantly lower with VMAT1 and VMAT2 (p=0.049 and p=0.006, respectively). Both VMAT1 and VMAT2 reduced the ID, however, only at the 5 Gy threshold for BG cases (p=0.011 and 0.005, respectively). VMAT achieved a lower spinal cord maximum dose and EUD for BG cases and higher optic nerve doses, otherwise no significant differences were observed. VMAT1 yielded the fastest treatment times and least MU. We conclude that VMAT offers faster treatment delivery for complex brain tumors while maintaining similar dosimetric qualities to IMRT. Selective dosimetric advantages in terms of spinal cord sparing and lowering the ID are observed favoring the use of an additional coplanar partial arc.
authors.affiliation: Department of Medical Physics, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
authors.forename: M T M
authors.initials: MT
authors.lastname: Davidson
authors.forename: G L
authors.initials: GL
authors.lastname: Masucci
authors.forename: M
authors.initials: M
authors.lastname: Follwell
authors.forename: S J
authors.initials: SJ
authors.lastname: Blake
authors.forename: W
authors.initials: W
authors.lastname: Xu
authors.forename: D J
authors.initials: DJ
authors.lastname: Moseley
authors.forename: P
authors.initials: P
authors.lastname: Sanghera
authors.forename: C S
authors.initials: CS
authors.lastname: Wong
authors.forename: J
authors.initials: J
authors.lastname: Perry
authors.forename: M
authors.initials: M
authors.lastname: Tsao
authors.forename: A
authors.initials: A
authors.lastname: Sahgal
mesh_terms: D001932:Brain Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D005909:Glioblastoma / Q000473:pathology / Q000532:radiotherapy*; D005910:Glioma / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D058958:Organs at Risk / Q000528:radiation effects; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D020266:Radiotherapy, Conformal / Q000379:methods; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome